Loss of CD99L2 contributed to temozolomide resistance and glioblastoma tumorigenesis based on Genome-scale CRISPR/Cas9 screening

Abstract excerpt

<title>Abstract</title> <p><bold>Introduction</bold>: Glioblastoma multiforme (GBM) is a highly aggressive and fatal malignancy of central nervous system. Temozolomide (TMZ) is the first-line chemotherapeutic drug for GBM, although drug resistance remains challenging. To date, <italic>MGMT</italic> promoter hypomethylation explains part of TMZ resistance cases. The purpose of this study was to utilize the whole h...

Topics

Open a Topic to create a Post that cites this publication.

• Cancer Mechanisms and Therapy
• CRISPR and Genetic Engineering
• CRISPR-Associated Protein 9
• CRISPR-Cas Systems
• Endonucleases
• Glioma Diagnosis and Treatment
• Histone Deacetylase Inhibitors Research
• MicroRNA in disease regulation

Identifiers and source

Literature Corpus work

c2666520-914f-57bd-b544-c6184c560a9a

DOI

10.21203/rs.3.rs-2206400/v1